AB 669 prohibits concurrent and retrospective medical‑necessity review of in‑network inpatient or residential substance use disorder (SUD) treatment for the first 28 days of a treatment plan, effective January 1, 2027, while allowing prior authorization consistent with existing statutory standards. The bill requires use of the ASAM Criteria for medical‑necessity determinations, sets limits on how frequently plans may initiate concurrent review after day 28, and imposes compressed timelines for internal and external expedited appeals.
The statute matters for clinicians, treatment facilities, and California-regulated health plans: it shifts initial decision authority toward the enrollee’s treating physician, shortens review and appeal deadlines for plans, and creates operational and cost implications for insurers and providers. The law excludes specified Medi‑Cal delivery systems and requires written discharge plans tied to ASAM placement criteria, which will affect discharge planning and care coordination protocols.
At a Glance
What It Does
Starting Jan 1, 2027, the bill bars concurrent and retrospective utilization review for the first 28 days of an in‑network inpatient or residential SUD treatment episode, while allowing prior authorization for that initial period under existing statutory standards. After day 28, plans may resume concurrent review no more frequently than every two weeks and must follow rapid internal and external expedited‑appeal timelines.
Who It Affects
California‑regulated health care service plans and insurers, in‑network inpatient and residential SUD facilities licensed under state law, program physicians who make medical‑necessity determinations, and enrollees with a diagnosis of substance use disorder. Specified Medi‑Cal behavioral health delivery systems and certain Medi‑Cal managed care plans are excluded.
Why It Matters
The bill elevates physicians’ placement decisions (via ASAM) at intake, limits payer oversight in the critical first month of care, and compresses appeals timelines — which will change prior‑authorization workflows, utilization‑review cadence, and financial exposure for plans and providers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 669 creates a protected initial treatment window for insured Californians receiving in‑network inpatient or residential SUD care. For the first 28 days of a treatment plan, the statute prohibits concurrent and retrospective utilization review, directing that medical‑necessity determinations be made by the enrollee’s treating physician and aligned with ASAM‑based criteria and existing statutory standards.
At the same time, plans retain the ability to require prior authorization for that initial 28‑day period, provided authorization procedures comport with the listed statutory standards.
The initial treatment plan itself is flexible: it does not have to specify a fixed number of days or a particular ASAM level of care. Physicians may include any mix or duration of levels — inpatient, residential, partial hospitalization, or intensive outpatient — as clinically necessary.
The bill also limits the protected status: if the program physician later determines a level of care is inappropriate, or the enrollee voluntarily leaves to seek a different level, the 28‑day protection does not apply to subsequent episodes. The text further clarifies that an additional treatment episode beginning within 180 days after admission for the first episode is not eligible for the 28‑day protection (i.e., it may be subject to utilization review).After the initial 28 days, plans may subject care to concurrent review but may not initiate those reviews more frequently than every two weeks.
If a plan decides continued inpatient or residential care is no longer medically necessary, it must notify the enrollee and the treating physician within 24 hours and allow an internal expedited appeal, which the plan must decide within 24 hours. The enrollee and physician may seek an external expedited appeal with the Department of Managed Health Care (or the department referenced) if filed within 72 hours; if the department upholds the denial, the plan must continue coverage for 24 hours after that determination and cannot bill the enrollee for more than the contract’s normal cost‑sharing for that period.The statute also requires facilities to produce a written discharge plan before discharge using the ASAM Criteria (or a subsequent nationally adopted placement standard) and mandates that all medical‑necessity review use those criteria.
The statute expressly excludes certain Medi‑Cal behavioral health delivery systems and specified Medi‑Cal managed care contracts, and it prevents plans from reducing or denying benefits on the basis of additional diagnoses beyond SUD.
The Five Things You Need to Know
Effective date: the protections and requirements take effect on January 1, 2027.
Initial 28‑day shield: concurrent and retrospective utilization review are barred for the first 28 days of an in‑network inpatient or residential SUD treatment plan, but plans may still require prior authorization for that period under existing standards.
Subsequent‑episode rule: any new treatment episode that begins within 180 days after admission for the first episode is not covered by the 28‑day review protection and may be subject to utilization review.
Appeals and notice timing: if a plan finds continued care not medically necessary after day 28 it must notify the enrollee and treating physician within 24 hours, issue an internal expedited appeal decision within 24 hours, and allow filing of an external expedited appeal within 72 hours; if the external appeal upholds denial the plan must continue coverage for 24 hours and limit billing to ordinary cost‑sharing.
ASAM and discharge requirements: the bill requires all medical‑necessity reviews and pre‑discharge planning to use the ASAM Criteria (or successor national placement standards) and mandates a written discharge plan before release.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
28‑day prohibition on concurrent and retrospective review
This provision prohibits plans from applying concurrent or retrospective utilization review to in‑network inpatient or residential SUD services for the first 28 days of a treatment plan, and specifies that medical necessity during that period is to be determined by the enrollee’s treating physician consistent with statutory standards. Practically, that limits a plan’s ability to cut short or claw back payment during the initial month of treatment, while preserving statutory medical‑necessity benchmarks as the legal standard.
Prior authorization may still be required for the initial period
Although the bill blocks concurrent and retrospective review during the first 28 days, it expressly allows plans to require prior authorization for that initial period so long as the authorization criteria align with referenced statutory standards. That means plans can still vet admissions in advance but cannot retrospectively or concurrently terminate coverage once the enrollment period begins, subject to the authorization rules.
Flexible initial treatment plan — no fixed day counts
The statute rejects any requirement that the initial treatment plan specify a preset number of days or a fixed level of care. Physicians can recommend any number of days and mix of ASAM levels (inpatient, residential, PHP, intensive outpatient) based on clinical need, which reduces administrative friction when levels of care need to change within the initial plan.
Limits on frequency of concurrent review and expedited appeal mechanics
After day 28, concurrent review is permitted but may not be initiated more frequently than every two weeks. If a plan determines care is no longer medically necessary, it must provide written notice to the enrollee and treating physician within 24 hours and resolve an internal expedited appeal within 24 hours. The statute preserves the right to file an external expedited appeal with the department within 72 hours; if the department upholds the denial, the plan must continue coverage for 24 hours post‑determination and cap the enrollee’s liability to standard copay/deductible/coinsurance amounts during that period.
Discharge planning and ASAM requirement
Facilities must provide a written discharge plan before the enrollee is discharged, using the ASAM Criteria or successor national placement standards. The statute also requires that all medical‑necessity reviews employ ASAM‑based placement criteria, meaning plan reviewers and providers must align assessments and placement decisions to that framework.
Definitions and cross‑references
This subsection maps the bill’s core terms — concurrent review, prior authorization, retrospective review, medically necessary, utilization review, and SUD — to definitions already in California law (Sections 1374.72 and 1374.721) and ties intensive outpatient/partial hospitalization to ASAM level definitions. Those references dictate which statutory standards apply to authorization and review workflows.
Medi‑Cal exclusions
The statute excludes Medi‑Cal behavioral health delivery systems and certain Medi‑Cal managed care plans that contract under specified Welfare and Institutions Code chapters. Those explicit carve‑outs leave Medi‑Cal programs governed by their existing state rules and contracts rather than by AB 669’s requirements.
Diagnostic neutrality
The law requires the covered in‑network benefits to be provided to all enrollees with an SUD diagnosis and bars plans from reducing or denying these benefits on the basis of additional comorbid diagnoses, which limits plans’ ability to use co‑occurring conditions as a basis for benefit denials.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Enrollees with substance use disorder: They gain protection from concurrent and retrospective review during the first 28 days of inpatient/residential treatment, reducing the risk of mid‑stay coverage terminations and retrospective payment denials during that critical early phase.
- Treating physicians and program clinicians: The bill elevates their medical‑necessity determinations (ASAM‑based) during intake and limits payer interference in the first month, giving clinicians greater authority to set placement and duration at the outset.
- Inpatient and residential SUD facilities: Facilities face reduced risk of mid‑stay denials or retroactive payment disputes for the initial 28 days, potentially improving revenue certainty for the start of an episode.
- Care coordinators and discharge planners: A mandatory, ASAM‑based written discharge plan strengthens care transitions by requiring explicit, standardized post‑discharge arrangements tied to national placement criteria.
Who Bears the Cost
- California‑regulated health care service plans and insurers: Plans absorb greater upfront financial exposure for initial 28‑day stays, face compressed notice and appeal timelines, and may incur higher administrative and payment risk.
- Employers sponsoring self‑insured (ERISA) health plans: While the bill targets state‑regulated plans, employer plans may face pressure or parallel contractual changes; ERISA preemption uncertainty may create uneven market effects and administrative complexity.
- Utilization‑review vendors and prior‑authorization teams: They must adjust workflows to accommodate the prior‑auth carve‑in, ASAM‑aligned reviews, and two‑week cadence for post‑28‑day concurrent reviews, which may increase operational costs.
- The Department overseeing external appeals: The compressed 72‑hour external appeal filing window and 24‑hour continuation requirement will increase the department’s caseload intensity and demand for rapid adjudication resources.
Key Issues
The Core Tension
The bill’s central dilemma is choosing between protecting early access and clinical autonomy for SUD treatment versus preserving payer oversight to limit unnecessary extended inpatient/residential stays: protecting the first 28 days reduces the risk of premature discharge and retrospective denials but shifts financial risk and administrative burden to plans and regulators, potentially incentivizing longer stays and straining review and appeals systems.
AB 669 packs obvious benefits for rapid access to SUD treatment but creates a handful of implementation tensions. First, the statute simultaneously bars concurrent and retrospective review for the first 28 days while allowing prior authorization for that same period; regulators will need to reconcile how prior‑authorization denials interact with the ban on concurrent/retr oactive review, and whether authorization denials can be appealed under the same compressed timelines.
Second, the bill names the enrollee’s treating physician as the initial determiner of medical necessity but requires consistency with statutory standards and ASAM—an ambiguity that invites disagreement about whether a plan can second‑guess a physician’s placement if the plan finds the ASAM application inconsistent.
Operationally, the two‑week limit on post‑28‑day concurrent reviews and the 24‑hour internal appeal decision requirement create tight turnaround expectations that many plans and facilities currently lack. Those timelines could force plans to sustain coverage longer than they otherwise would while they marshal clinical review, or conversely, to expedite denials that then generate frequent external appeals.
The exclusion of specified Medi‑Cal systems also raises equity and coordination questions: individuals who shift between Medi‑Cal and commercial coverage may experience different protections, complicating continuity of care. Finally, the requirement to use ASAM (or successor standards) anchors determinations to a particular clinical framework, but reliance on ASAM updates, interpretive differences, and variable provider familiarity may produce inconsistent placement decisions and administrative disputes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.